Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FDA Asks GSK To Change Labeling For Lovaza To Add Atrial Fibrillation On Sept.4th,2012

|Includes: Amarin Corporation PLC (AMRN), AZN, GSK, MRK, PFE

FDA has asked Glaxo to change labeling for Lovaza to show Atrial Fibrillation .This is when heart rhythm is irregular.

This letter and pdf was published on Sept.4th,2012.

This risk helps doctors prescribe Vascepa which is better for Cardiac known factors like LDL--Lovaza raises LDL,where Vascepa does not(actually lowers it.)

Disclosure: I am long AMRN.